Amelubant
Amelubant has been in phase II clinical trials by Boehringer Ingelheim for the treatment of cystic fibrosis, chronic obstructive pulmonay disease, bronchial asthma and rheumatoid arthritis. However, this research has been discontinued.
In 2002, orphan drug designation was received in E.U. for the treatment of cystic fibrosis.
General Information
Update Date：2016-04-26
- Drug Name：
- Amelubant
- Research Code：
- BIIL-284; BIIL-284-BS
- Trade Name：
- MOA：
- Leukotriene B4 receptor antagonist
- Indication：
- Cystic fibrosis (CF); Chronic obstructive pulmonary disease (COPD); Bronchial asthma; Rheumatoid arthritis (RA)
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Boehringer Ingelheim (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-18
|
Molecular Weight | 538.63 | ||||||||||||
| Formula | C33H34N2O5 | |||||||||||||
| CAS No. | 346735-24-8 (Amelubant); | |||||||||||||
| Chemical Name | Carbamic acid, N-[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy]phenyl]iminomethyl]-, ethyl ester | |||||||||||||
| Amelubant （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||